Zestra Laboratories Elects New Board of Directors
Zestra Laboratories, Inc., global innovator in clinically proven intimacy products for women’s sexual health, announces the election of four new members to its board of directors, bringing the current number of board members to five. Its flagship product, Zestra® is available at more than 41,000 drugstore and retail outlets in the United States. It is the only women's topical intimacy product that is clinically proven to increase female sexual arousal, pleasure, desire/libido and satisfying sexual experiences for women; everything else available for women are simply lubricants. To date, there are still no FDA-approved prescription drug treatments for any form of female sexual dysfunction (FSD).
“We are gratified with the addition of our new directors, who bring extensive experience and serial successes in both prescription pharmaceuticals and consumer product brands to our Board,” Martin Crosby, Founder and Acting CEO of Zestra, said. “Their proven track records and their industry knowledge, business insights, and capital formation expertise will be invaluable to Zestra, as we accelerate our growth in 2008 and beyond.”
In 2008, Zestra plans to extend its product line in women’s health, introduce a male sexual health product, and increase its market penetration in Europe and Asia.
The 2008 Board of Directors took office on February 27, 2008. The board of directors includes: Anthony A. Rascio; Jay Popli; Reed Bolton Byrum; Martin Crosby, and Gerald Pribanic.
Anthony A. Rascio - Rascio was most recently Senior Vice President and Corporate Secretary of Esprit Pharma, a pharmaceutical company focused on the genitourinary (GU) and women’s healthcare markets. Rascio was instrumental in Esprit Pharma successfully completing a Series B funding round, raising $90 million in financing from a group of leading venture capital and private equity investors. Allergan (NYSE: AGN) acquired Esprit Pharma in a $370 million all-cash transaction in October 2007. Rascio formerly served as Senior Vice President and General Counsel for ESP Pharma where he was responsible for acquisitions, licensing, financing, patent, trademark, and copyright matters. He was instrumental in the sale of ESP Pharma to PDL Biopharma, Inc (NASDAQ: PDLI). Before that, he was Vice President and General Counsel of Roberts Pharmaceutical Corporation where he counseled the company in raising capital in excess of $400 million, negotiated multi-million dollar licensing arrangements with US, European, and Japanese companies, and helped lead the merger with Shire Pharmaceuticals of London (LSE: SHPGY). Earlier in his career, Rascio served as Legal Director, International Division, for Schering-Plough. Rascio received his undergraduate and J.D. degrees from Fordham University. read more in businesswire.com
“We are gratified with the addition of our new directors, who bring extensive experience and serial successes in both prescription pharmaceuticals and consumer product brands to our Board,” Martin Crosby, Founder and Acting CEO of Zestra, said. “Their proven track records and their industry knowledge, business insights, and capital formation expertise will be invaluable to Zestra, as we accelerate our growth in 2008 and beyond.”
In 2008, Zestra plans to extend its product line in women’s health, introduce a male sexual health product, and increase its market penetration in Europe and Asia.
The 2008 Board of Directors took office on February 27, 2008. The board of directors includes: Anthony A. Rascio; Jay Popli; Reed Bolton Byrum; Martin Crosby, and Gerald Pribanic.
Anthony A. Rascio - Rascio was most recently Senior Vice President and Corporate Secretary of Esprit Pharma, a pharmaceutical company focused on the genitourinary (GU) and women’s healthcare markets. Rascio was instrumental in Esprit Pharma successfully completing a Series B funding round, raising $90 million in financing from a group of leading venture capital and private equity investors. Allergan (NYSE: AGN) acquired Esprit Pharma in a $370 million all-cash transaction in October 2007. Rascio formerly served as Senior Vice President and General Counsel for ESP Pharma where he was responsible for acquisitions, licensing, financing, patent, trademark, and copyright matters. He was instrumental in the sale of ESP Pharma to PDL Biopharma, Inc (NASDAQ: PDLI). Before that, he was Vice President and General Counsel of Roberts Pharmaceutical Corporation where he counseled the company in raising capital in excess of $400 million, negotiated multi-million dollar licensing arrangements with US, European, and Japanese companies, and helped lead the merger with Shire Pharmaceuticals of London (LSE: SHPGY). Earlier in his career, Rascio served as Legal Director, International Division, for Schering-Plough. Rascio received his undergraduate and J.D. degrees from Fordham University. read more in businesswire.com
Posts
Post a Comment